Clinical Trial: Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

Study Status: Completed
Recruit Status: Unknown status
Study Type: Observational



Official Title: Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

Brief Summary:

Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer. We wanted to show or investigate, that:

  • ANXA3 can be detected in urine after standard digital rectal examination.
  • ANXA3 has better specificities than tPSA, in particular in the grey zone of PSA
  • ANXA3 can help avoid unnecessary biopsies
  • ANXA3 can in the long run replace PSA as a marker